New Application of Photodynamic Disinfection to be Funded by UK’s Medical Research Council: Catheter-Associated Infection Prevention

Today we announced a significant new opportunity for both our company and for the Photodynamic Therapy (PDT) world. By awarding our groups a £ 1 million award to develop PDT based products to prevent catheter associated infections, the UK Government has validated the need for solutions as well as endorsed the potential of Photodynamic Therapy in this role.

Together with a team of multi-disciplined experts at University College London (UCL), Ondine will collaborate on an important new initiative which leverages our combined 30 plus years of history in photodynamics to develop a new major class of medical devices based on Photodynamic disinfection. The new class of products will address the multi-billion dollar issue of catheter-associated infections, firmly placing Ondine as a leading supplier of innovative non-antibiotic products addressing  the $35-$45 billion per year healthcare-associated infection (HAI) market1. Urinary tract infections (UTIs) are considered to be the largest source of HAIs, representing about 30% of all reported cases, with catheter-associated UTIs representing 75% of this number.

Photodynamic Disinfection, also known as aPDT (antimicrobial Photodynamic Therapy by the scientific community), has been proven over the past ten years to be instantly effective at killing biofilms and safe for use on human tissue.  UCL and Ondine are research and development partners that jointly created and commercialized Periowave™, the first application of Photodynamic Disinfection in the dental market.  To date, over 70,000 Periowave™ treatments have been successfully deployed through a large and growing global base of dental clinics.

Having successfully commercialized this first Photodynamic Disinfection based product , Ondine has shifted its focus onto the needs and opportunities of the enormous healthcare-associated infection  market. CDC estimates that HAIs cost the US healthcare system $35-$45 billion annually and has further identified that there are currently few non-antibiotic solutions or competitors in this space, especially for CAI prevention.  In an era of heightened sensitivity to the global antibiotic resistance crisis, the nonresistance forming attributes of Photodynamic Disinfection’s are gaining greater endorsement and support as represented by UK’s Medical Research Council Award.

Ondine is developing non-antibiotic, anti-biofilm products to reduce surgical site infections (MRSAid™) and ventilator-associated pneumonia (Endowave™).  Non-antibiotic nasal decolonization  (MRSAid™) is a disruptive technology that allows for instant MRSA and MSSA decolonization without generating resistance, a major concern associated with the topical antibiotics currently being used for this application. Endowave™ is a medical device that is designed to reduce the biofilm growth in breathing tubes of patients under extended intubation.  Additionally, Ondine is supporting the development of Sinuwave™ for chronic sinusitis and Vitalwave™, a product for the prevention of mother-to-child transmission of HIV.

The addition of products that can prevent catheter-associated infections to our product line is an enormous opportunity for Ondine. Ondine is well positioned to participate in addressing three of the leading sources of HAIs, reinforcing our position as the global leader in PDT development.

  1. Scott RD. The Direct Medical Costs of Healthcare-Associated Infections in U.S. Hospitals and the Benefits of Prevention, 2009.
Related Posts Plugin for WordPress, Blogger...

2 Responses to “New Application of Photodynamic Disinfection to be Funded by UK’s Medical Research Council: Catheter-Associated Infection Prevention”

  1. you got a very fantastic website, Gladiola I observed it through yahoo.

Leave a Reply

Staypressed theme by Themocracy